TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
RMD

ResMed Inc

Healthcare · Medical Instruments & Supplies

211.90$ -5.1% vs. previous close Closing price · As of: Aug 7, 2026

Statements

Segments

US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of ResMed Inc (RMD). It shows which part of the business is growing — and which one is holding it back.

Revenue by business segment

Revenue by business segment — RMD
Segment Q3 2024 Q4 2024 Q1 2025 Q3 2025 Q4 2025 Q1 2026
Sleep And Breathing Health [Member] $1.07B 87.2% $1.13B 87.8% $1.13B 87.5% $1.17B 87.6% $1.26B 88.3% · +17.6% $1.26B 88.1% · +12.0%
Residential Care Software $156.8M 12.8% $156.5M 12.2% $161.2M 12.5% $166.1M 12.4% $166.9M 11.7% · +6.4% $170.9M 11.9% · +9.2%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Revenue by product line

Revenue by product line — RMD
Segment Q3 2024 Q4 2024 Q1 2025 Q3 2025 Q4 2025 Q1 2026
Sleep And Breathing Health [Member] $1.07B 87.2% $1.13B 87.8% $1.13B 87.5% $1.17B 87.6% $1.26B 88.3% · +17.6% $1.26B 88.1% · +12.0%
Residential Care Software $156.8M 12.8% $156.5M 12.2% $161.2M 12.5% $166.1M 12.4% $166.9M 11.7% · +6.4% $170.9M 11.9% · +9.2%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.

Data as of: August 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?